Clinical Trials

Lymphomas / Myelomas / Leukemias

Recruitment stopped
Ongoing Recruitment

Multiple Myeloma (Plasmocytoma)

GMMG-HD 6

(first-line)
Title:A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
Indication:Multiple Myeloma
Type of study:Phase III
Contact: Studiensekretariat GMMG (Kontaktperson)
[studiensekretariat.GMMG@med.uni-heidelberg.de]
Investigator: Prof. Dr. Hartmut Goldschmidt (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02495922
EudraCT: 2014-003079-40 (siehe EU klinisches Studienregister)

Anti-CD38 Antikörper-Studie (MOR202C101)

(second-line)
Title:A Phase I/IIa, Open-Label, Multicentre, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of the Human Anti-CD38 Antibody MOR03087 as Monotherapy and in Combination With Standard Therapy in Subjects With Relapsed/Refractory Multiple Myeloma
Indication:rezidiviertes oder refraktäres Multiples Myelom
Type of study:Phase I/II
Contact: Prof. Dr. Hartmut Goldschmidt (Kontaktperson)
[hartmut.goldschmidt@med.uni-heidelberg.de]
Investigator: Dr. Marc Raab (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT01421186
EudraCT: 2009-015942-50 (siehe EU klinisches Studienregister)

BIRMA (CLGX818ADE01T)

(second-line)
Title:LGX818 in Combination With MEK162 in Refractory or Relapsed Multiple Myeloma Patients With BRAFV600E or BRAFV600K Mutation
Indication:Multiple Myeloma, Neoplasms, Plasma Cell
Type of study:Phase II
Contact: Prof. Dr. Hartmut Goldschmidt (Kontaktperson)
[hartmut.goldschmidt@med.uni-heidelberg.de]
Investigator: Dr. Marc Raab (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02834364
EudraCT: 2014-004597-42 (siehe EU klinisches Studienregister)

GMMG-DANTE

(second-line)
Title:Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment Including Subjects Undergoing Hemodialysis: A Phase 2, Open-label, Multicenter Trial
Indication:Multiple Myeloma, Neoplasms, Plasma Cell, Renal Insufficiency
Type of study:Phase II
Contact: PD Dr. Jens Hillengass (Kontaktperson)
[jens.hillengass@med.uni-heidelberg.de]
Investigator: Prof. Dr. Hartmut Goldschmidt (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02977494
EudraCT: 2016-000433-51 (siehe EU klinisches Studienregister)

MEDI4736 / FUSION-MM-003

(second-line)
Title:A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Indication:Multiple MyelomaNeoplasms, Plasma Cell
Type of study:Phase II
Contact: Prof. Dr. Hartmut Goldschmidt (Kontaktperson)
[hartmut.goldschmidt@med.uni-heidelberg.de]
Investigator: Dr. Marc Raab (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02807454
EudraCT: 2016-001209-17 (siehe EU klinisches Studienregister)

MP0250-CP201 / MP-Studie

(second-line)
Title:A Phase 2 Open-label, Single-arm, Multicenter Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Refractory and Relapsed Multiple Myeloma
Indication:Multiple Myeloma, Neoplasms, Plasma Cell
Type of study:Phase II
Contact: Prof. Dr. Hartmut Goldschmidt (Kontaktperson)
[hartmut.goldschmidt@med.uni-heidelberg.de]
Investigator: Prof. Dr. Hartmut Goldschmidt (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03136653
EudraCT: 2016-002771-10 (siehe EU klinisches Studienregister)

OPTIMISMM (CC-4047-MM-007)

(second-line)
Title:A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Indication:Multiple Myeloma Neoplasms, Plasma Cell
Type of study:Phase III
Contact: Dr. Marc Raab (Kontaktperson)
[marc.raab@med.uni-heidelberg.de]
Investigator: Prof. Dr. Hartmut Goldschmidt (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT01734928
EudraCT: 2014-000268-17 (siehe EU klinisches Studienregister)

Transregio-79

(diagnostisch, Screening)
Title:Examination of Bone Defects and Microcirculation Using Volume Computed Tomography and Dynamic Contrast-enhanced Magnetic Resonance Imaging
Indication:Multiple Myeloma, Spinal Fractures Osteoporosis
Type of study:Phase N/A
Contact: Radiologie DKFZ (Kontaktperson)
[-]
Investigator: Prof. Dr. Stefan Delorme (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT01374412
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

Verfettungsstudie

(diagnostisch, Screening)
Title:Durch Strahlentherapie induzierte Verfettung des Knochenmarks in der diffusionsgewichteten MRT (DWI).
Indication:n.a.
Type of study:Phase N/A
Contact: Prof. Dr. Stefan Delorme (Kontaktperson)
[s.delorme@dkfz-heidelberg.de]
Investigator: Prof. Dr. Stefan Delorme (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

PREAMBLE

(epidemiologisch)
Title:Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Indication:Multiple Myeloma Neoplasms, Plasma Cell
Type of study:Phase IV
Contact: Prof. Dr. Hartmut Goldschmidt (Kontaktperson)
[hartmut.goldschmidt@med.uni-heidelberg.de]
Investigator: Dr. Marc Raab (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT01838512
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

NSMM-5001 / INSIGHT MM

Title:A Global, Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - the INSIGHT-MM Study
Indication:Multiple Myeloma, Neoplasms, Plasma Cell
Type of study:Phase IV
Contact: Prof. Dr. Hartmut Goldschmidt (Kontaktperson)
[hartmut.goldschmidt@med.uni-heidelberg.de]
Investigator: Prof. Dr. Hartmut Goldschmidt (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02761187
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

Leukemias

AMLSG23-14 / Palbo-AL-1

(second-line)
Title:Phase Ib/IIa Study of Palbociclib in MLL-rearranged Acute Leukemias AMLSG 23-14/Palbo-AL-1
Indication:Leukemia, Lymphoid Leukemia, Myeloid Leukemia, Myeloid, Acute Precursor Cell Lymphoblastic Leukemia-Lymphoma
Type of study:Phase I/II
Contact: Prof. Dr. Stefan Fröhling (Kontaktperson)
[stefan.froehling@nct-heidelberg.de]
Investigator: Prof. Dr. Stefan Fröhling (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02310243
EudraCT: 2014-003647-34 (siehe EU klinisches Studienregister)

PNH Register

(diagnostisch, Früherkennung, Screening)
Title:Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry
Indication:Hemoglobinuria, Paroxysmal
Type of study:Phase N/A
Contact: Judith Schladitz (Kontaktperson)
[judith.schladitz@med.uni-heidelberg.de]
Investigator: Dr. med. Christoph Lutz (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT01374360
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

CLL-Register

(epidemiologisch)
Title:An Observational Registration Study of Infusion-related Adverse Events at Administration of Mabthera (Rituximab) in the Treatment of Chronic Lymphocytic Leukemia.
Indication:Leukemia, Lymphoid Leukemia, Lymphocytic, Chronic, B-Cell
Type of study:Phase N/A
Contact: Judith Schladitz (Kontaktperson)
[judith.schladitz@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Peter Dreger (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT01072240
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

GMALL-Register

(epidemiologisch)
Title:GMALL-Register und Biomaterialbank Biomaterialsammlung und prospektive Datenerfassung zu Diagnostik, Behandlung und Krankheitsverlauf der ALL des Erwachsenen
Indication:Leukaemia
Type of study:Phase N/A
Contact: Inge Hotz (Kontaktperson)
[inge.hotz@med.uni-heidelberg.de]
Investigator: Dr. med. Christoph Lutz (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

Target Nis (CAMN107ADE04)

(epidemiologisch)
Title:Beobachtungsstudie zur Sicherheit und Wirksamkeit von Tasigna® (Nilotinib) sowie zur Therapietreue der Patienten in der Behandlung der Philadelphia-Chromosom-positiven chronischen myeloischen Leukämie in chronischer Phase bei Patienten mit Resistenz oder Unverträglichkeit gegenüber einer Vorbehandlung einschließlich Glivec® (Imatinib).
Indication:Philadelphia-Chromosom-positiven chronischen myeloischen Leukämie
Type of study:Phase N/A
Contact: Judith Schladitz (Kontaktperson)
[judith.schladitz@med.uni-heidelberg.de]
Investigator: Dr. med. Christoph Lutz (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

AIOP-BFM ALL 2009

(pädiatrisch)
Title:International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
Indication:LeukemiaLeukemia, LymphoidPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Type of study:Phase III
Contact: Donate Jakoby (Study Nurse)
[donate.jakoby@med.uni-heidelberg.de]
Investigator: Dr. med. Wolfgang Behnisch (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT01117441
EudraCT: 2007-004270-43 (siehe EU klinisches Studienregister)

ALL SCT FORUM / ALL-SCT-ped-FORUM

(pädiatrisch)
Title:Allogenic stem cell transplantation in children and adolescents with acute lymphoblastic leukaemia - FORUM (For Omitting Radiotherapy Under Majority age)
Indication:acute lymphoblastic leukaemia
Type of study:Phase III
Contact: Donate Jakoby (Study Nurse)
[donate.jakoby@med.uni-heidelberg.de]
Investigator: PD Dr. med. Johann Greil (Prüfer)
Trial Register: No trial registry number given.
EudraCT: 2012-003032-22 (siehe EU klinisches Studienregister)

IVAC-ALL-1

(pädiatrisch)
Title:Prospective phase I/II study: Patient-individualized peptide vaccination based on whole exome sequencing with adjuvant GM-CSF in children with relapsed acute lymphoblastic leukemia
Indication:lymphatischer Leukämie
Type of study:Phase I/II
Contact: Sabine Brokmeier (Study Nurse)
[s.brokmeier@dkfz-heidelberg.de]
Investigator: Prof. Dr. med. Olaf Witt (Prüfer)
Trial Register: No trial registry number given.
EudraCT: 2015-005281-29 (siehe EU klinisches Studienregister)

Int-Re_ALL / IntReALL-SR-2010

(pädiatrisch)
Title:International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group
Indication:Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Lymphoid
Type of study:Phase III
Contact: Donate Jakoby (Study Nurse)
[donate.jakoby@med.uni-heidelberg.de]
Investigator: Dr. med. Wolfgang Behnisch (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT01802814
EudraCT: 2012-000793-30 (siehe EU klinisches Studienregister)

LCH III-Studie

(pädiatrisch)
Title:Treatment Protocol of the Third International Study For Langerhans Cell Histiocytosis
Indication:Histiocytosis, Langerhans-Cell
Type of study:Phase III
Contact: Donate Jakoby (Study Nurse)
[donate.jakoby@med.uni-heidelberg.de]
Investigator: Dr. med. Wolfgang Behnisch (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT00276757
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

Napoleon Register

(Registerstudie)
Title:National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup
Indication:Leukemia, Promyelocytic, Acute
Type of study:Phase III
Contact: Marianne Gawlik (Kontaktperson)
[maria.gawlik@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Alwin Krämer (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02192619
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

SAL AML Register

(Registerstudie)
Title:AML-Register und Biomaterial Datenbank der Studienallianz Leukämie
Indication:Leukämie
Type of study:Phase N/A
Contact: Marianne Gawlik (Kontaktperson)
[maria.gawlik@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Alwin Krämer (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

Relaza2 / Vidaza

(supportive care trial)
Title:Treatment of Patients With MDS or AML With an Impending Hematological Relapse With Azacitidine (Vidaza)
Indication:LeukemiaSyndromeMyelodysplastic SyndromesPreleukemiaLeukemia, Myeloid, AcuteLeukemia, Myeloid
Type of study:Phase II
Contact: Diana Six (Kontaktperson)
[Diana.Six@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Alwin Krämer (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT01462578
EudraCT: 2010-022388-37 (siehe EU klinisches Studienregister)

AC220-007

Title:A Phase 3 Open-label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects With Tyrosine Kinase 3 - Internal Tandem Duplication (FLT3-ITD) Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
Indication:Leukemia, MyeloidLeukemia, Myeloid, Acute
Type of study:Phase III
Contact: Diana Six (Kontaktperson)
[Diana.Six@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Alwin Krämer (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02039726
EudraCT: 2013-004890-28 (siehe EU klinisches Studienregister)

AC220-A-U302 / Quantum first

Title:A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
Indication:Leukemia, MyeloidLeukemiaLeukemia, Myeloid, Acute
Type of study:Phase III
Contact: Diana Six (Kontaktperson)
[Diana.Six@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Alwin Krämer (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02668653
EudraCT: 2015-004856-24 (siehe EU klinisches Studienregister)

BLAST (UKH062014)

Title:A Double- Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of BL-8040 Addition to Consolidation Therapy in AML Patients
Indication:Leukemia, Myeloid, Acute
Type of study:Phase II
Contact: Diana Six (Kontaktperson)
[Diana.Six@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Alwin Krämer (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02502968
EudraCT: 2014-002702-21 (siehe EU klinisches Studienregister)

CLL13 / UNI-KOELN-2751

Title:A Phase 3 Multicenter, Randomized, Prospective, Open-label Trial of Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab Plus Venetoclax (RVe) Versus Obinutuzumab (GA101) Plus Venetoclax (GVe) Versus Obinutuzumab Plus Ibrutinib Plus Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
Indication:Leukemia, Lymphocytic, Chronic, B-CellLeukemia, Lymphoid
Type of study:Phase III
Contact: Beatrice Müller (Kontaktperson)
[beatrice.mueller@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Peter Dreger (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02950051
EudraCT: 2015-004936-36 (siehe EU klinisches Studienregister)

CLL2-GIVe

Title:A Prospective, Open-label, Multicentre Phase-II Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Physically Fit or Unfit Patients With Previously Untreated Chronic Lymphocytic Leukemia (Cll) With tp53 Deletion (17p-) and/or Mutation
Indication:LeukemiaLeukemia, Lymphocytic, Chronic, B-CellLeukemia, Lymphoid
Type of study:Phase II
Contact: Judith Schladitz (Kontaktperson)
[judith.schladitz@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Peter Dreger (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02758665
EudraCT: 2015-004606-41 (siehe EU klinisches Studienregister)

CLLRUmbrella2 (GS-US-401-2076)

Title:A Prospective, Randomized, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of GS-4059 and Entospletinib With and Without Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia
Indication:Leukemia, Lymphocytic, Chronic, B-CellLeukemia, Lymphoid
Type of study:Phase II
Contact: Monika Fischer (Kontaktperson)
[monika.fischer@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Peter Dreger (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02983617
EudraCT: 2016-002768-15 (siehe EU klinisches Studienregister)

CLLTX1 / ML29747

Title:Obinutuzumab Containing Conditioning Regimen for CLL Patients and Patients With Richter`s Transformation Requiring an Allogeneic Stem Cell Transplantation
Indication:Leukemia, Lymphocytic, Chronic, B-CellLeukemia, Lymphoid
Type of study:Phase II
Contact: Claudia Bruch (Kontaktperson)
[claudia.bruch@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Peter Dreger (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03153514
EudraCT: 2015-00568-32 (siehe EU klinisches Studienregister)

FLYSYN-101

Title:First in Man Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Fc-optimized FLT3 Antibody FLYSYN for the Treatment of Acute Myeloid Leukemia Patients With Minimal Residual Disease
Indication:LeukemiaLeukemia, MyeloidLeukemia, Myeloid, Acute
Type of study:Phase I
Contact: Marianne Gawlik (Study Nurse)
[maria.gawlik@med.uni-heidelberg.de]
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02789254
EudraCT: 2016-000236-17 (siehe EU klinisches Studienregister)

MLN9708 - C16011

Title:A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Indication:Amyloidosis
Type of study:Phase III
Contact: Cristina Bernardo (Kontaktperson)
[cristina.bernardo@med.uni-heidelberg.de]
Investigator: Dr. med. Stefan Schönland (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT01659658
EudraCT: 2011-005468-10 (siehe EU klinisches Studienregister)

MorphoSys Studie (MOR208C2059

Title:A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of MOR00208 Combined With Idelalisib or Venetoclax in Patients With Relapsed or Refractory CLL/SLL Previously Treated With Bruton's Tyrosine Kinase (BTK) Inhibitor
Indication:Leukemia, Lymphocytic, Chronic, B-CellLeukemia, Lymphoid
Type of study:Phase II
Contact: Monika Fischer (Kontaktperson)
[monika.fischer@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Peter Dreger (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02639910
EudraCT: 2015-002915-14 (siehe EU klinisches Studienregister)

Nilo-deep-R (CAMN107ADE20)

Title:A Phase IV Single Arm, Multicenter, Open-label Study Assessing Deep Molecular Response in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive CML in Chronic Phase After Two Years of Treatment With Nilotinib 300mg BID
Indication:Leukemia, Myeloid Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Type of study:Phase IV
Contact: Inge Hotz (Kontaktperson)
[inge.hotz@med.uni-heidelberg.de]
Investigator: Dr. med. Christoph Lutz (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02546674
EudraCT: 2015-000968-34 (siehe EU klinisches Studienregister)

PCI-32765CAN3001 (Ibrutinib)

Title:A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study
Indication:Follicular Leukemia, Lymphoid Lymphoma, B-Cell Lymphoma, Mantle-Cell Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Large B-Cell, Diffuse
Type of study:Phase III
Contact: Judith Schladitz (Kontaktperson)
[judith.schladitz@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Peter Dreger (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT01804686
EudraCT: 2012-004225-24 (siehe EU klinisches Studienregister)

TIGER / CML-V

Title:Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy
Indication:Leukemia, Myeloid Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Type of study:Phase III
Contact: Judith Schladitz (Kontaktperson)
[judith.schladitz@med.uni-heidelberg.de]
Investigator: Dr. med. Christoph Lutz (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT01657604
EudraCT: 2010-024262-22 (siehe EU klinisches Studienregister)

TUD-2DAUNO-058 / Dauno Double

Title:Randomized Comparison Between Two Dose Levels of Daunorubicin and Between One Versus Two Cycles of Induction Therapy for Adult Patients With Acute Myeloid Leukemia =60 Years
Indication:Leukemia, Myeloid Leukemia, Myeloid, Acute
Type of study:Phase III
Contact: Diana Six (Kontaktperson)
[Diana.Six@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Alwin Krämer (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02140242
EudraCT: 2013-003191-12 (siehe EU klinisches Studienregister)

TUD-Apollo-064 / Apollo Studie

Title:A Randomized Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA and Idarubicin Versus Standard ATRA and Anthracyclines-based Chemotherapy (AIDA Regimen) for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
Indication:Leukemia, Promyelocytic, Acute
Type of study:Phase III
Contact: Marianne Gawlik (Kontaktperson)
[maria.gawlik@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Alwin Krämer (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02688140
EudraCT: 2015-001151-68 (siehe EU klinisches Studienregister)

TUD-MIDOKI-052 / Midokit (PKC412)

Title:A Single-arm Phase II Trial to Assess the Efficacy of Midostaurin (PKC412) Added to Standard Primary Therapy in Patients With Newly Diagnosed c-KIT or FLT3-ITD Mutated t(8;21) AML
Indication:Leukemia, Myeloid Leukemia, Myeloid, Acute
Type of study:Phase II
Contact: Marianne Gawlik (Kontaktperson)
[maria.gawlik@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Alwin Krämer (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT01830361
EudraCT: 2011-002567-17 (siehe EU klinisches Studienregister)

Lymphomas

TTACT (Riemser/ Zetrum 15)

(epidemiologisch)
Title:Eine nicht-interventionelle prospektive Erhebung zur Verträglichkeit und Wirksamkeit von Thiotepa-haltigen Hochdosis-Chemotherapien (HDCT) mit anschließender autologer Stammzelltransplantation im routinemäßigen Einsatz bei erwachsenen Patienten mit mit B- oder T-Zell-Lymphomen (Non Hodgkin Lymphome oder Hodgkin Lymphome) mit oder ohne ZNS-Beteiligung oder mit primärem ZNS-Lymphom
Indication:B- oder T-Zell-Lymphomen
Type of study:Phase N/A
Contact: Audrey Tan (Kontaktperson)
[audrey.tan@med.uni-heidelberg.de]
Investigator: Prof. Dr. med. Knut Schäkel (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

ALCL-Relapse

(pädiatrisch)
Title:ALCL-Relapse: Treatment protocol for relapsed anaplastic large cell lymphoma of childhood and adolescence 2. Amendment Juni 2012
Indication:Rezidive von großzellig anaplastischen Lymphomen, alle Stadien
Type of study:Phase III
Contact: Renate Sedlak (Study Nurse)
[renate.sedlak@med.uni-heidelberg.de]
Investigator: Dr. med. Wolfgang Behnisch (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT00317408
EudraCT: 2005-003321-57 (siehe EU klinisches Studienregister)

EuroNet-PHL-C2

(pädiatrisch)
Title:Second international inter-Group Study for classical Hodgkin's Lymphoma in childrens an adolescents
Indication:Hodgkin's Lymphoma
Type of study:Phase III
Contact: Renate Sedlak (Kontaktperson)
[renate.sedlak@med.uni-heidelberg.de]
Investigator: Dr. med. Wolfgang Behnisch (Prüfer)
Trial Register: No trial registry number given.
EudraCT: 2012-004053-88 (siehe EU klinisches Studienregister)

NHL-BFM Registry 2012

(pädiatrisch, epidemiologisch)
Title:B-NHL BFM 04: Multizentrische Beobachtungsstudie zur Behandlung von Kindern und Jugendlichen mit reifem B-Zell Non-Hodgkin-Lymphom oder B-ALL
Indication:NHL-BFM registry 2012: Registry of the NHL-BFM study group for all subtypes of Non-Hodgkin Lymphoma diagnosed in children and adolescents
Type of study:Phase N/A
Contact: Renate Sedlak (Study Nurse)
[renate.sedlak@med.uni-heidelberg.de]
Investigator: Dr. med. Wolfgang Behnisch (Prüfer)
Trial Register: No trial registry number given.
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

ALTERNATIVE Studie (Mz-135)

Title:Eine Phase II Studie Zur Beurteilung Der Wirksamkeit Von Rituximab in Der Salvage- Und Hochdosistherapie Mit Autologer Stammzelltransplantation Bei Patienten Mit B-Zell-Non-Hodgkin-Lymphom
Indication:Lymphoma, Non-Hodgkin
Type of study:Phase II
Contact: Beatrice Müller (Kontaktperson)
[beatrice.mueller@med.uni-heidelberg.de]
Investigator: Dr. med. Sascha Dietrich (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02099292
EudraCT: 2014-005164-15 (siehe EU klinisches Studienregister)

B-CAP (Uni-Koeln-1707)

Title:Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma - a GHSG-NLG Intergroup Phase II Trial -
Indication:Lymphoma, Hodgkin Disease
Type of study:Phase II
Contact: Audrey Tan (Kontaktperson)
[audrey.tan@med.uni-heidelberg.de]
Investigator: Dr. Julia Meißner (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02191930
EudraCT: 2013-003990-89 (siehe EU klinisches Studienregister)

CHARLY Trial

Title:PHASE-II STUDY ON THE VALUE OF POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER THIOTEPA-BASED HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA
Indication:non-Hodgkin Lymphoma
Type of study:Phase II
Contact: Diana Six (Kontaktperson)
[Diana.Six@med.uni-heidelberg.de]
Investigator: Dr. med. Sascha Dietrich (Prüfer)
Trial Register: No trial registry number given.
EudraCT: 2015-003920-30 (siehe EU klinisches Studienregister)

GOAL-Studie

Title:The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma
Indication:Lymphoma, Non-Hodgkin
Type of study:Phase II
Contact: Claudia Bruch (Kontaktperson)
[claudia.bruch@med.uni-heidelberg.de]
Investigator: PD Dr. med. Mathias Witzens-Harig (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02499003
EudraCT: 2014-00480-21 (siehe EU klinisches Studienregister)

HD-R3i (Uni-Koeln-1443)

Title:A Prospective, Randomized, Placebo-controlled, Multicenter, International Phase I/II Trial of RAD001 (Everolimus) in Combination With DHAP as Induction Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
Indication:Lymphoma, Hodgkin Disease
Type of study:Phase I/II
Contact: Audrey Tan (Kontaktperson)
[audrey.tan@med.uni-heidelberg.de]
Investigator: Dr. Julia Meißner (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT01453504
EudraCT: 2010-021086-73 (siehe EU klinisches Studienregister)

HD21(Uni-Koeln-1762)

Title:HD21 for Advanced Stages Treatment Optimization Trial in the First-line Treatment of Advanced Stage Hodgkin Lymphoma; Comparison of 6 Cycles of Escalated BEACOPP With 6 Cycles of BrECADD
Indication:LymphomaHodgkin Disease
Type of study:Phase III
Contact: Audrey Tan (Kontaktperson)
[audrey.tan@med.uni-heidelberg.de]
Investigator: Dr. Julia Meißner (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02661503
EudraCT: 2014-005130-55 (siehe EU klinisches Studienregister)

MK-3475-204/KEYNOTE-204

Title:A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
Indication:LymphomaHodgkin Disease
Type of study:Phase III
Contact: Audrey Tan (Kontaktperson)
[audrey.tan@med.uni-heidelberg.de]
Investigator: Dr. Julia Meißner (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02684292
EudraCT: 2015-005053-12 (siehe EU klinisches Studienregister)

NIVAHL

Title:Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma
Indication:LymphomaHodgkin Disease
Type of study:Phase II
Contact: Audrey Tan (Kontaktperson)
[audrey.tan@med.uni-heidelberg.de]
Investigator: Dr. Julia Meißner (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03004833
EudraCT: Not stated. Non-interventional studies and studies not controlled by the Medicines Act do not have a EudraCT number.

Optimal>60-Studie / DSHNHL 2009-1

Title:Improvement of Outcome and Reduction of Toxicity in Elderly Patients With CD20+ Aggressive B-Cell Lymphoma by an Optimised Schedule of the Monoclonal Antibody Rituximab, Substitution of Conventional by Liposomal Vincristine, and FDG-PET Based Reduction of Therapy in Combination With Vitamin D Substitution
Indication:Aggression Lymphoma, B-Cell
Type of study:Phase III
Contact: Judith Schladitz (Kontaktperson)
[judith.schladitz@med.uni-heidelberg.de]
Investigator: Dr. med. Sascha Dietrich (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT01478542
EudraCT: 2010-019587-36 (siehe EU klinisches Studienregister)

SGN 35 - 014 / ECHELON-2-Studie

Title:A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Indication:Lymphoma Lymphoma, Large-Cell, Anaplastic Lymphoma, Non-Hodgkin Lymphoma, T-CellLymphoma, T-Cell, Peripheral
Type of study:Phase III
Contact: Claudia Bruch (Kontaktperson)
[claudia.bruch@med.uni-heidelberg.de]
Investigator: PD Dr. med. Mathias Witzens-Harig (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT01777152
EudraCT: 2012-002751-42 (siehe EU klinisches Studienregister)

TRIANGLE Studie

Title:Internationale, unverblindete, dreiarmige, parallel randomisierte, Phase III Studie mit 6 alternierenden Kursen R-CHOP/R-DHAP (21 Tage pro Zyklus) gefolgt von autologer Stammzelltransplantation versus ebendieser Kombination mit Ibrutinib in Induktion und Erhaltungstherapie (2 Jahre) oder dem experimentellem Studienarm ohne autologe Stammzelltransplantation.
Indication:mantle cell Lymphoma
Type of study:Phase III
Contact: Beatrice Müller (Kontaktperson)
[beatrice.mueller@med.uni-heidelberg.de]
Investigator: Dr. med. Sascha Dietrich (Prüfer)
Trial Register: No trial registry number given.
EudraCT: 2014-001363-12 (siehe EU klinisches Studienregister)